In team, in collaboration with our drug distribution and diversion control experts, worked with bipartisan, bicameral members of Congress to develop and advance legislation designed to move closer to real-time monitoring of controlled substance sales, which we believe would be a major breakthrough in efforts to identify suspicious orders before they are shipped.